|
Pronunciation |
|
(naf
AZ oh leen & fen NIR a
meen) |
|
|
U.S. Brand
Names |
|
Naphcon-A® Ophthalmic
[OTC] |
|
|
Generic
Available |
|
No |
|
|
Synonyms |
|
Pheniramine and Naphazoline |
|
|
Pharmacological Index |
|
Ophthalmic Agent, Vasoconstrictor |
|
|
Use |
|
Topical ocular vasoconstrictor |
|
|
Pregnancy Risk
Factor |
|
C |
|
|
Contraindications |
|
Hypersensitivity to naphazoline, pheniramine, or any
component |
|
|
Adverse
Reactions |
|
1% to 10%:
Systemic effects due to absorption:
Cardiovascular: Hypertension, cardiac irregularities
Endocrine & metabolic: Hyperglycemia |
|
|
Drug
Interactions |
|
MAO inhibitors (hypertensive crisis possible) |
|
|
Usual Dosage |
|
1-2 drops every 3-4 hours |
|
|
Mental Health: Effects
on Mental Status |
|
May cause nervousness or dizziness |
|
|
Mental Health:
Effects on Psychiatric
Treatment |
|
TCAs and MAOIs may potentiate the pressor response of decongestants; monitor
for changes in response |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
No effects or complications reported |
|
|
Patient
Information |
|
Discontinue drug and consult physician if ocular pain or visual changes
occur, ocular redness or irritation, or condition worsens or persists more than
72 hours |
|
|
Nursing
Implications |
|
Discontinue drug and consult physician if ocular pain or visual changes
occur, ocular redness or irritation, or condition worsens or persists more than
72 hours |
|
|
Dosage Forms |
|
Solution, ophthalmic: Naphazoline hydrochloride 0.025% and pheniramine 0.3%
(15 mL) |
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|